This study suggests that cancer‐driving mutations have a range of metabolic heterogeneities across tissues that have implications for the detection and therapeutic targeting of cancer, in particular when studying the metabolic effects of TP53 mutation we highlight that consideration must be taken for both the tissue context, and the mutational type. The gene discussed is TP53; the disease is cancer.